INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia^[1].

LSD1^[1]

INCB059872 (25 nM; 48 hours; 293T cells) increases enhancer activity and gene expression^[1].
INCB059872 (25 nM; 24 hours; THP-1 cells) makes THP-1 show a growth defect within one cell doubling time or approximately 3 days. INCB059872 (100 nM; 24 hours; MV-4–11 cells) treated MV-4–11 cells continues to grow as DMSO-treated cells for multiple cell divisions. INCB059872 (THP-1 cells) regulates PRO-seq analysis identifies genes and enhancers^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

INCB059872 (10 mg/kg; p.o.; 0, 4, or 6 days) makes single-cell RNA-seq revealing changes in bone marrow progenitor populations^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

386.53

C₂₃H₃₄N₂O₃

1802909-49-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Johnston G, et al. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. Gene. 2020;752:144758.